Klaudia Borgiasz, Aleksandra Szewerniak, Karolina Palmąka, Antoni Łazarczyk, Sławomir Smolik, Ludmiła Węglarz
Possibilities of personalizing the pharmacotherapy of type 2 diabetes mellitus based on the genetic profile of the patient
Diabetes mellitus is one of the diseases with the highest and constantly increasing morbidity. The plurality of pathogenic factors and mechanisms of type 2 diabetes leads to many challenges in treatment. In addition, the patient’s response to pharmacotherapy is characterized by individual variability mostly dependent from the genetic profile and the lifestyle. Genetic changes lead to different therapeutic effects and intolerance of used medicinal substances. As a result of increased interest in pharmacogenetics and greater availability of genetic research, the term “personalized medicine” is increasingly used in the pharmacotherapy of type 2 diabetes. It was found that the occurrence of given genetic variants in the patient predisposes to obtaining different responses to hypoglycemic drugs, such as metformin, sulfonylureas, incretin drugs or sodium glucose cotransporter 2 inhibitors. Personalization of treatment of the patient may allow obtaining effective pharmacotherapy, as well as no uncomfortable side effects.
Keywords: diabetes mellitus, therapy, pharmacogenetics, personalized medicine.
© Farm Pol, 2019, 75 (6): 300–305